Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms, Unknown Primary × pembrolizumab × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 122 Melanoma 56 Squamous Cell Carcinoma of Head and Neck 55 Parkinson Disease 4, Autosomal Dominant Lewy Body 50 Lung Neoplasms 48 Triple Negative Breast Neoplasms 41 Breast Neoplasms 39 Neoplasm Metastasis 36 Neoplasms 35 Colorectal Neoplasms 33 Carcinoma, Renal Cell 27 Stomach Neoplasms 22 Endometrial Neoplasms 22 Carcinoma, Transitional Cell 22 Ovarian Neoplasms 21 Uterine Cervical Neoplasms 19 Urinary Bladder Neoplasms 19 Pancreatic Neoplasms 18 Head and Neck Neoplasms 18 Esophageal Neoplasms 18 Carcinoma 16 Carcinoma, Hepatocellular 12 Recurrence 11 Glioblastoma 11 Carcinoma, Squamous Cell 11 Mouth Neoplasms 9 Prostatic Neoplasms 8 Esophageal Squamous Cell Carcinoma 8 Lymphoma 7 Laryngeal Neoplasms 7

Interventions

sintilimab 1 pembrolizumab 1 Whole Genome Sequencing 1 Sequence Analysis, RNA 1 Magnetic Resonance Spectroscopy 1 Fluorodeoxyglucose F18 1 FAPI-46 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03752333 2026-01-22

CUPem

Imperial College London

Phase 2 Completed

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡